UK-based MeiraGTx Holdings plc (Nasdaq: MGTX) announced a strategic investment of up to USD 400 million from Oberland Capital Management LLC, structured to fund commercialization preparation for two late-stage gene therapy programs approaching potential regulatory approval. The deal is designed to avoid equity dilution on the bulk of the capital, addressing MeiraGTx's need to finance launch activities without further shareholder dilution following a USD 100 million public offering completed in April 2026.
The agreement provides up to USD 375 million in royalty-based financing and up to USD 25 million in equity. The initial funded amount is USD 135 million, comprising USD 125 million in royalty financing and a USD 10 million equity investment. Three additional USD 50 million tranches are available at MeiraGTx's option, tied to: positive Phase II data from the AQUAx2 study for AAV2-hAQP1 in 2027; regulatory approval of botaretigene sparoparvovec (bota-vec) in 2027; and regulatory approval of AAV2-hAQP1 in 2028. A further USD 100 million is available by mutual agreement for new products or business development. Oberland Capital also holds the right to purchase an additional USD 15 million in equity. In exchange for the royalty financing, Oberland Capital receives low single-digit capped royalties on net sales of AAV2-hAQP1, bota-vec, and AAV-AIPL1 following regulatory approval. MeiraGTx retains a buyback right on the entire funded royalty note at specified amounts at any time. Royalty payments are capped at a multiple of the funded amounts.
AAV2-hAQP1 is a gene therapy for grade 2/3 late radiation-induced xerostomia, targeting patients with chronic dry mouth following head and neck radiotherapy. The asset holds FDA Breakthrough Therapy and RMAT designations and is currently in final enrollment stages of the Phase II AQUAx2 study, with data expected 12 months after the last patient is treated, a potential BLA filing in H1 2027, and a targeted US launch in early 2028. Bota-vec is an AAV-based gene therapy for X-linked retinitis pigmentosa, reacquired from Johnson & Johnson in April 2026 for USD 25 million upfront; MeiraGTx holds GMP manufacturing licenses and several hundred vials of product ready for post-approval patient treatment. Oberland Capital has deployed similar royalty-financing structures with other gene therapy companies, including Opus Genetics and ImmunityBio, reflecting a pattern of backing late-stage programs with near-term commercial catalysts across the sector.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article